Can a shot in the deltoid stimulate mucus in the airways? The answer is "No" ... Then, how can vaccines be effective?
Vaccine Effectiveness Myth (Part 2): A 30-year lie on misplaced vaccines - Covid Myth Buster News
In matters of vaccines, more than anything else, the devil is in the detail.
Vaccine effectiveness can be very binary and complete failure is quite easy. The immune system being a sophisticated bio-software; sensitivity is very strong. Every detail, every step of the way, is key: the area of injection, the injection tool, the immune context of the patient, the schedule … Where and how you inject the product can make or break the entire vaccine effectiveness.
A few years back, I was fortunate enough to do a deep-dive into a next generation anti-cancer vaccine technology, advising a ground-breaking immune therapeutics company in Paris. As I was comparing their technology with competition, I remember being surprised at the effort, time and money they had dedicated to fine-tuning the delivery of the vaccine. We were talking years in additional development, and consequently millions of dollars invested, to test where and how to best deliver the vaccine.
Why? Why had they paid so much attention to the delivery, and not their competitors? Well, there was your attention to detail … and it sure paid off, the company ended up with response rates close to 90% when its competitors were achieving less than 10% … an enormous difference with the potential1 to save millions from cancer.
In the accelerated development of anti-COVID vaccines, the focus was essentially on developing the right “code” to transfer to the immune system, mainly on the relatively narrow Spike protein, as you all know by now. They also focused on the best delivery vehicle - the lipid nanoparticle - and optimal manufacturing processes. However, vaccine effectiveness depends on many other factors. A systems approach was needed, not a pinpoint solution approach. It’s not enough to find and to present the right antigens - with the right quality - to the immune system, even packed into the latest and greatest technology…
Unfortunately, after a year of vaccination and 9.5 billion doses, vaccine failure is visible to everybody to acknowledge: unforeseen transmission, explosion of cases… If you believe “Our World In Data”, we’ve had 240 million infections in 2021 - when we vaccinated like never before. We only had 70 million in 2020 when we had no vaccines...
Based on case numbers, the vaccine is not even putting a dent in the epidemic.
Either by media-induced panic, by sheer incompetence, or possibly by customary corruption, vaccine stakeholders have presented a completely false narrative on anti-COVID vaccine effectiveness.
For nearly a year now, I have been exposing two critical inconsistencies in terms of the location of the vaccine-induced immunity that make it nearly impossible for these vaccines to be effective:
How can an injection in the deltoid stimulate an immunity in the mucus?
Respiratory virus like SARS-COV-2 typically propagate in the mucus: mouth, nose, digestive tract and lungs. For propagation to be stopped in the mucus, notably in the lungs, a preemptive immune arsenal needs to be stimulated there. This is exactly what occurs once recovered from a natural infection: a sterilising immunity is provided by potent resident memory T and B-cells - along with neutralising IgA antibodies - that are positioned in large numbers as a sentinel force to kill in-the-egg any starting infection.
I have addressed this at length in my June article comparing natural immunity and vaccine-induced immunity as well as in my August article on pre-existing immunity. I am not alone in thinking along these lines; many renowned scientists share a similar perspective that intramuscular vaccines cannot work for mucosal viruses:
Professor Edward J. Steele of Australia in a recent interview on Asia Pacific Today titled “The Origins Of Covid-19 & Why The Vaccines Don't Work” also made the same point.
Professor Michael W. Russell in the US hinted the same thing in an article “Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection”.
Already in 1992, McGhee et al in an article titled “The mucosal immune system: from fundamental concepts to vaccine development” had pointed to this fallacy.
“It is surprising that despite our current level of understanding of the common mucosal immune system, almost all current vaccines are given to humans by the parenteral 2 route. Systemic immunisation is essentially ineffective for induction of mucosal immune responses.” McGhee et al, 1992
Professor Akiko Iwasaki3 at Yale , in a very smart study, demonstrated that only a mucosal vaccine can be fully effective against sexual herpes because it stimulates mucosal resident memory T-cells. She and her team “paired”4 the blood flow of one naive mouse with an immune mouse with both resident and circulating T-cells. By doing so, she was able to compare the effectiveness of mucosal immunity vs systemic immunity, the naive mouse benefiting only of the circulating memory T-cells. Mucosal wins by and large. Circulating T-cells helped ultimately in a second stage, but in the case of SARS-COV-2 all adults have circulating memory T-cells because of cross-immunity5 from other common colds. In other words, if anti-COVID vaccines don’t create resident memory immunity in the mucus, they provide no to very limited value. This video will help you understand (32’).
In conclusion, it is very unlikely that any intramuscular vaccines can ever work to stop COVID; the vaccines are injected in the wrong location: the muscle, too far away from the virus entry point to stimulate any response there. This is not related to mRNA or DNA technologies, attenuated virus vaccines are also de facto ineffective.
This is simply a question of location of where the vaccine is delivered… And the fact that millions have been vaccinated against the flu in the arm every year for decades, most likely uselessly shouldn’t change this reality …
Given the emphasis of vaccine manufacturers and public health authorities on antibodies, you’re all probably thinking:
- “Hey Marc ?! What about neutralising antibodies?”
The question is: What can antibodies do to stop a propagation that is cell-to-cell?
To start, vaccine-induced antibodies are also misplaced … circulating in the blood away from the mucus. And, even if a few antibodies were to migrate to the mucus, they would very much be useless against a virus that propagates cell-to-cell (see picture below). Fundamentally, cell-to-cell propagation means the virus expansion happens out-of-reach of antibodies (at least before Omicron). Antibodies can’t bind with viruses that are inside cells, only T-cells can chase down virions inside cells by instructing infected cells to self-destruct…
Cell-to-cell Propagation of SARS-COV-2 6
Imagine you want to catch someone when he gets out of a building, and he never does: he’s actually using tunnels from one building to the next. Well these vaccines are essentially useless because not only is the virus using tunnels, but you’re not even in the same town!
The virus is inside a Mucustown building while antibodies are outside a building in Bloodville!
Looks like a missed meeting to me. What do you think? …
In their Phase I trial, nearly 30% of the stage IV cancer patient who received the entire protocole survived more than 4 years
Parenteral: administered or occurring elsewhere in the body than the mouth and alimentary canal.
Pr Akiko Iwasaki is an Investigator of the HHMI and Waldemar Von Zedtwitz Professor of Department of Immunobiology, and of Department of Molecular Cellular and Developmental Biology at the Yale School of Medicine. Her research focuses on the mechanisms of immune defense against viruses at the mucosal surfaces.
Parabiosis combines two living organisms which are joined together surgically and develop single, shared physiological systems, here the blood flow.
Cross-immunity is an effective immunity granted from past infections with “cousin” viruses, a form of natural vaccination.
Source: Ultrastructural analysis of SARS-CoV-2 interactions with the host cell via high resolution scanning electron microscopy